ArticlePloS one2026
TL1A serves as a positive regulator to promote adipocyte differentiation.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adipogenesis, the intricate process of differentiation from preadipocytes or mesenchymal stem cells into mature adipocytes, is crucial for the formation and metabolic function of adipose tissues in mammals. The TNF ligand-related molecule 1A (TL1A) is a type II transmembrane protein belonging to the TNF superfamily. Inflammation is involved in the whole process of adipocyte cell formation and obesity development. To investigate the potential influence of TL1A on adipocyte development, we examined mouse embryo fibroblasts (MEFs) and 3T3-L1 cells. Our findings indicated that TL1A-treated MEFs exhibited an elevated rate of spontaneous adipogenesis, with a significant enhancement in adipocyte formation upon induction with a combination of insulin, dexamethasone and methylisobutylxanthine. This increased adipogenesis was evidenced by augmented lipid droplet formation and elevated expression of several adipogenic markers. Specifically, there was an upregulation of early-stage adipogenesis genes, including Krox20, KLF5, C/EBPβ and C/EBPδ, as well as late-stage adipogenesis regulators such as KLF15, C/EBPα, PPARγ and aP2. Moreover, TL1A significantly upregulated the protein expression of adipogenic markers (C/EBPα, C/EBPβ, PPARγ, CD36 and aP2) in MEFs and 3T3-L1 cells. Mechanistically, TL1A enhanced the phosphorylation of yes-associated protein 1 (YAP1), which led to cytoplasmic retention. Ultimately, TL1A inhibited the stabilization and nuclear transfer of β-catenin in MEFs, probably through regulating the upstream protein YAP1. Taken together, TL1A promoted adipogenic differentiation of MEFs and 3T3-L1 cells in vitro, which partly via inhibiting YAP1 mediated β-catenin signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.